Domov › Skleroderma › Kalifornija
Klinične študije za Skleroderma v Kalifornija
13 študij za Skleroderma išče udeležence na lokacijah v Kalifornija.
Mesta v Kalifornija
Uradno besedilo študije (angleško)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Vključevanje udeležencevFaza 1
Starost 18–74 · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- in še 1
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
Vključevanje udeležencevFaza 1/2
Starost 18–70 · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
Vključevanje udeležencevFaza 1
Starost 18–70 · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
Vključevanje udeležencevFaza 1/2
Starost 18–75 · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- in še 3
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
Vključevanje udeležencevFaza 1
Starost 18–75 · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- in še 2
Vključevanje udeležencevFaza 1
Starost 12–70 · Vsi spoli · Posodobljeno 22. maj 2026 · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 7. maj 2025 · NCT05892614Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.